SunRock Biopharma, S.L is rated 3 out of 5 in the category biotechnology. Read and write reviews about SunRock Biopharma, S.L. SunRock develops therapeutical antibodies targeted at the Chemokine Receptor 9, CCR9, a new therapeutic target whose over-expression is correlated with the invading capacity of the Acute Lymphoblastic Leukemia of T Lymphocites, the Chronic Lymphoblastic Leukemia of T Lymphocites and solid tumors such as the ovary cancer, prostate cancer, breast cancer and melanoma.
Address
Avda. Barcelona s/n. Edificio CIMUS.
Company size
1-10 employees
Headquarters
Santiago de Compostela, A Coruña